Dmitry Velmeshev, PhD
Dr. Dmitry Velmeshev is a postdoctoral research fellow at the University of California, San Francisco. Velmeshev received his PhD from the University of Miami, where he studied molecular mechanisms of autism spectrum disorder. He then joined the laboratory of Dr. Arnold Kriegstein at UCSF. His research focuses on applying single-cell genomics and bioinformatics techniques to understand how specific cell types change during human brain development and in disease, especially neurodevelopmental disorders.
Sequencing the Brain
Download this listicle to learn more about bulk tissue genomics and single-cell RNA-seq analysis of the mammalian brain and investigating cell type-specific changes in brain disorders
How To Guide
How To Address NGS Challenges
Download this guide to learn how to select the appropriate NGS method and sequencing platform, deal with samples of variable quality, and set up and manage the data analysis pipeline.
How To Guide
How To Optimize Next-Generation Sequencing Workflows
Download this guide to learn more about techniques such as bulk tissue RNA sequencing, single-nucleus RNA sequencing and whole-genome DNA sequencing.
5 Specialized Techniques for Fragment-Based Drug Discovery
In this listicle, we will discuss the principles of FBDD, how it compares to other drug discovery approaches, as well as highlighting various techniques that allow for lead compound identification with FBDD.
Recent Advances and Applications of Single-Cell Sequencing
Here, we review the most commonly adopted technologies and workflows available for single-cell sequencing and discuss current research studies adopting such approaches.
Recent Advances in Single-Cell Genomics Techniques
Single-cell genomics methods, such as single cell RNA sequencing (scRNA-seq), involve labeling biomolecules originating from individual cells, therefore enabling high-throughput molecular analysis at single-cell resolution. This article explores the recent advances in single-cell genomics techniques, and the applications of such technologies.
Whole-Exome Sequencing at the Dawn of Personalized Medicine
Deciphering the first complete sequence of the human genome in 2003 required a combined effort of scientists from 20 institutions and $3 billion of funding. Over the last decade, whole-exome sequencing (WES) established itself as a method that successfully balances cost and the output of useful data for diagnostic or research applications. Here, we look at how WES is used in both the laboratory and the clinic, and why it is a preferred method of choice in such areas.